Drug Treatment for Bladder Cancer
Authors:
S. C. Schmid; J. E. Gschwend; M. Retz
Authors place of work:
Urologische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universität
Published in the journal:
Urol List 2015; 13(2): 31-34
Summary
Perioperative treatment of muscle invasive bladder cancer has become standard in the last years. New agents like PD1/PD-L1 inhibitors have opened the door for immunomodulating therapy in metastasized bladder cancer. This article focuses on data which has changed or has the potential to change the medical treatment of advanced bladder cancer with a review of literature and proceedings of major meetings (EAU, ASCO, GU-ASCO, AUA).
Key words:
immunomodulators, radical cystectomy, neoadjuvant chemotherapy, adjuvant chemotherapy, palliative
Zdroje
1. Hautmann RE, Gschwend JE, de Petriconi RC et al. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006; 176(2): 486–492.
2. Advanced bladder cancer (ABC) meta-analysis collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48(2): 202–205.
3. Kitamura H, Tsukamoto T, Shibata T et al. Randomized phase III trial of neoadjuvant chemotherapy (NAC) with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) followed by radical cystectomy (RC) compared with RC alone for muscle-invasive bladder cancer (MIBC): Japan Clinical Oncology Group study, JCOG0209. J Clin Oncol 2013; 31 (Suppl): abstr. 4526.
4. Griffiths G, Hall R, Sylvester R et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29(16): 2171–2177. doi: 10.1200/JCO.2010.32.3139.
5. Fairey AS, Daneshmand S, Quinn D et al. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Urol Oncol 2013; 31(8): 1737–1743. doi: 10.1016/j.urolonc.2012.07.005.
6. Pal SK, Ruel NH, Wilson TG et al. Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer. Clin Genitourin Cancer 2012; 10(4): 246–250. doi: 10.1016/j.clgc.2012.08.004.
7. Galsky MD, Harshman LC, Crabb SJ et al. Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). J Clin Oncol 2014; 32 (Suppl 5): abstr. 4512.
8. Plimack ER, Hoffman-Censits JH, Kutikov A et al. Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): final results of a multicenter phase II study. J Clin Oncol 2014; 32 (Suppl 5): abstr. 4513.
9. Leow JJ, Martin-Doyle W, Rajagopal PS et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 2014; 66(1): 42–54. doi: 10.1016/j.eururo.2013.08.033.
10. Advanced bladder cancer (ABC) meta-analysis collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005; 48(2): 189–199.
11. Sternberg CN, Skoneczna IA, Kerst JM et al. Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder. J Clin Oncol 2014; 32 (Suppl 5): abstr. 4500.
12. Sternberg CN, Bellmunt J, Sonpavde G et al. ICUD-EAU International Consultation on Bladder Cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol 2013; 63(1): 58–66. doi: 10.1016/j.eururo.2012.08.010.
13. Tjokrowidjaja, A, Lee C, Stockler MR. Does chemotherapy improve survival in muscle-invasive bladder cancer (MIBC)? A systematic review and meta-analysis (MA) of randomized controlled trials (RCT). J Clin Oncol 2013; 32 (Suppl 5): abstr. 4544.
14. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23(21): 4602–4608.
15. Bellmunt J, von der Maase H, Mead GM et al. Randomized phase III study comparing paclitaxel//cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012; 30(10): 1107–1113. doi: 10.1200/JCO.2011.38.6979.
16. Bachner M, De Santis M. Second-line therapy in bladder cancer. Curr Opin Urol 2009; 19(5): 533–539. doi: 10.1097/MOU.0b013e32832eb473.
17. Sonpavde G, Sternberg CN, Rosenberg JE et al. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 2010; 11(9): 861–870. doi: 10.1016/S1470-2045(10)70086-3.
18. Powles T, Vogelzang NJ, Fine GD et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). J Clin Oncol 2014; 32 (Suppl 5): abstr. 5011.
Štítky
Paediatric urologist UrologyČlánok vyšiel v časopise
Urological Journal
2015 Číslo 2
Najčítanejšie v tomto čísle
- Urodynamics – Procedure and Indications
- Tackling the Percutaneous Nephrolithotomy
- Dysfunction of Ejaculation, Sexual Desire and Orgasm in Men after Spinal Cord Injury Depending on the Extent of Spinal Lesions
- Evaluation of the Calcium Stone Former